Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Figure 4 Comparative analysis of early-stage and advanced pancreatic ductal adenocarcinoma.
A: Serum glycan peak (GP)2 and GP7 levels differ significantly between early (stage I and II) and advanced (stage III and IV) pancreatic ductal adenocarcinoma; B: Serum cancer antigen (CA)19-9 and CA242 levels differ significantly between early (stage I and II) and advanced (stage III and IV) pancreatic ductal adenocarcinoma. aP < 0.05, bP < 0.01. GPs: Glycan peaks; CA19-9: Cancer antigen 19-9.
- Citation: Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer. World J Gastrointest Oncol 2024; 16(3): 659-669
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/659.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.659